Once-Daily pill may ease life for kidney transplant patients
NCT ID NCT03979365
First seen Jan 05, 2026 · Last updated May 02, 2026 · Updated 9 times
Summary
This study looked at kidney transplant patients taking anti-rejection medication. It compared a once-daily pill (Envarsus XR) to a twice-daily pill (immediate-release tacrolimus) to see if the once-daily option led to fewer side effects, better medication adherence, and improved quality of life. 261 adults who had a kidney transplant participated, and researchers measured symptoms like trembling, muscle cramps, and gum swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.